Recombinant factor VIIa use in cardiac surgery - Expanding the arsenal therapy for intractable bleeding?

A. Kogan*, M. Berman, M. Stein, B. A. Vidne, E. Raanani

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A 72-year-old patient was admitted for mitral valve replacement because of infective endocarditis. Severe intractable bleeding in the early postoperative period was successfully treated with recombinant activated factor VII (rFVIIa). Thereafter, recovery was uneventful, and the patient was discharged on postoperative day 16. The current clinical aspects and experience of rFVIIa use in cardiac surgery are discussed.

Original languageEnglish
Pages (from-to)569-571
Number of pages3
JournalJournal of Cardiovascular Surgery
Volume45
Issue number6
StatePublished - 2004
Externally publishedYes

Keywords

  • Cardiac surgical procedures
  • Factor VII
  • Mitral valve
  • Postoperative hemorrhage
  • Surgery

Fingerprint

Dive into the research topics of 'Recombinant factor VIIa use in cardiac surgery - Expanding the arsenal therapy for intractable bleeding?'. Together they form a unique fingerprint.

Cite this